|
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Investor FAQs
Contact Us
Shareholder Tools
Email Alerts
Search Investor Relations
|
Press Releases
All Releases
 |
Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-938 in Patients with Chronic Hepatitis C
Jul 28, 2010
|
13.3 KB |
|
| |
- PSI-938 single ascending dose study in healthy volunteers supports progression to 7 day monotherapy study in HCV infected patients
- PSI-938 was generally safe and well tolerated with no dose-limiting toxicity
- Further results from single ascending and multiple ascending dose trials are expected in the third quarter 2010...
|
|
Pharmasset Announces Submission of Abstracts to AASLD Liver Meeting Including an Interim Analysis of Roche's Phase 2b PROPEL Trial of RG7128
Jun 9, 2010
|
13.7 KB |
|
| |
PRINCETON, N.J., June 9, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), wh...
|
|
Pharmasset to Present at Two Upcoming Investor Conferences
Jun 7, 2010
|
11.4 KB |
|
| |
PRINCETON, N.J., June 7, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Jefferies 2010 Global Life Sciences Conference being held June 9 to 11, 2010 at the Grand Hyatt, New York, NY and the ThinkEquity Mid Year Check-Up on Healthcare Conference being held June 16, 2010 at t...
|
|
Pharmasset to Present at the Citi Global Healthcare Conference
May 20, 2010
|
11.2 KB |
|
| |
PRINCETON, N.J., May 20, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Citi Global Health Care Conference being held May 26 to 27, 2010 at the New York Hilton, New York, NY. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the...
|
|
Pharmasset Announces Exercise of Underwriters' Overallotment Option
May 18, 2010
|
9.6 KB |
|
| |
PRINCETON, N.J., May 18, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the underwriters of its recent stock offering have exercised their option to purchase an additional 480,000 shares of common stock. The net proceeds to Pharmasset, Inc., after deducting the underwriting discount, from the sale of t...
|
|
Pharmasset Prices Public Offering of Common Stock
May 13, 2010
|
9.7 KB |
|
| |
PRINCETON, N.J., May 13, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the pricing of an underwritten public offering of 3,200,000 shares of its common stock at an offering price of $29.00 per share. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated off...
|
|
Pharmasset Announces Proposed Public Offering of Common Stock
May 11, 2010
|
10.3 KB |
|
| |
PRINCETON, N.J., May 11, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it has commenced an underwritten public offering, subject to market and other conditions, of 3,200,000 shares of its common stock pursuant to an effective shelf registration statement. Pharmasset intends to grant to the underwr...
|
|
Pharmasset Reports Fiscal Second Quarter 2010 Financial Results
May 5, 2010
|
18.7 KB |
|
| |
PRINCETON, N.J., May 5, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2010.
Financial Re...
|
|
Pharmasset Affirms Safety and Continued Progress in Clinical Development of RG7128
May 4, 2010
|
11.1 KB |
|
| |
PRINCETON, N.J., May 4, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus (HCV) in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today ...
|
|
Pharmasset Announces Results of a 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection
May 4, 2010
|
15.8 KB |
|
| |
PRINCETON, N.J., May 4, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the efficacy and preliminary safety results from its 28 day phase 2a study with PSI-7977 dosed once daily (QD) in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin), the current standard of care (SOC) in p...
|
|
Pharmasset to Present at the Bank of America Merrill Lynch Health Care Conference
Apr 30, 2010
|
11.0 KB |
|
| |
PRINCETON, N.J., April 30, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Bank of America Merrill Lynch Health Care Conference being held May 11 to 13, 2010 at the Grand Hyatt Hotel, New York, NY. Schaefer Price, Pharmasset's President and Chief Executive Officer, will prov...
|
|
Pharmasset Announces Interim Data from an Ongoing 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection
Apr 15, 2010
|
11.9 KB |
|
| |
PRINCETON, N.J., April 15, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys(R) (peginterferon alfa 2a) and Copegus(R) (ribavirin) in patients with hepatitis C virus (HCV) g...
|
|
Pharmasset to Present New Data on RG7128 and PSI-7977 at the EASL Conference
Apr 13, 2010
|
11.7 KB |
|
| |
PRINCETON, N.J., April 13, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the oral presentation of new sustained virologic response (SVR) follow-up data in hepatitis C virus (HCV) genotype 2 and 3 non-responder patients treated for 28 days with RG7128 in combination with the standard of care (SOC), Pegasys(R)...
|
|
Pharmasset Initiates First Time in Human Study of PSI-938 for the Treatment of Hepatitis C
Apr 8, 2010
|
11.2 KB |
|
| |
PRINCETON, N.J., April 8, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has initiated in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset recently filed an...
|
|
Pharmasset to Present at the Canaccord Adams Hepatitis C Conference
Mar 29, 2010
|
11.1 KB |
|
| |
PRINCETON, N.J., March 29, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Canaccord Adams Hepatitis C Conference being held Thursday April 1, 2010 at the Peninsula Hotel, New York, NY. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide a review...
|
|
Pharmasset to Present at Cowen and Company 30th Annual Healthcare Conference
Mar 3, 2010
|
12.2 KB |
|
| |
PRINCETON, N.J., March 3, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Cowen and Company 30th Annual Healthcare Conference being held from March 8 to 11, 2010 at the Boston Copley Marriot Place, Boston, MA. Schaefer Price, Pharmasset's President and Chief Executive Office...
|
|
Pharmasset Announces Complete Enrollment of RG7128 Phase 2b Clinical Study
Feb 17, 2010
|
11.5 KB |
|
| |
PRINCETON, N.J., Feb 17, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset.
Roche...
|
|
Pharmasset Reports Fiscal First Quarter 2010 Financial Results
Feb 9, 2010
|
15.9 KB |
|
| |
PRINCETON, N.J., Feb 09, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended December 31, 2009.
...
|
|
Pharmasset Announces Exercise of Underwriter's Option
Jan 29, 2010
|
9.4 KB |
|
| |
PRINCETON, N.J., Jan 29, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the underwriter of its recent stock offering has exercised its option to purchase an additional 230,400 shares of common stock. The net proceeds to Pharmasset, Inc., after deducting the underwriting discount, from the sale of these...
|
|
Pharmasset Prices Underwritten Offering of Common Stock
Jan 28, 2010
|
9.5 KB |
|
| |
PRINCETON, N.J., Jan 28, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the pricing of an underwritten offering of 1,600,000 shares of its common stock at a price of $18.75. After the underwriting discount and estimated offering expenses, Pharmasset expects to receive net proceeds of approximately $28....
|
|
|
= add release to Briefcase |
